navtemadlin + pembrolizumab

N**avtemadlin + pembrolizumab** is an investigational combination therapy for cancer, currently evaluated as a maintenance regimen in locally advanced and metastatic non-small cell lung cancer. Navtemadlin (KRT-232) is a small molecule, orally administered, that functions as a selective MDM2 inhibitor and works by reactivating p53 tumor suppressor activity, leading to cell cycle arrest and apoptosis in tumor cells reliant on wild-type p53. Pembrolizumab is a humanized IgG4 monoclonal antibody that blocks programmed cell death protein 1 (PD-1), lifting PD-1-mediated inhibition of T cell activity, thus restoring antitumor immune responses. Pembrolizumab is developed and marketed by Merck & Co under the brand name Keytruda and is approved for multiple cancer types, whereas navtemadlin remains investigational. The combination seeks to synergize immune checkpoint inhibition with pro-apoptotic tumor targeting[5][2].

Other names

navtemadlinpembrolizumab